TaiwanJ Pharmaceuticals Co., Ltd.

Taipei Exchange 6549.TWO

TaiwanJ Pharmaceuticals Co., Ltd. Price to Book Ratio (P/B) on January 14, 2025

TaiwanJ Pharmaceuticals Co., Ltd. Price to Book Ratio (P/B) is NA on January 14, 2025, a NA change year over year. Price to book ratio compares the stock price to the book value per share; above 1 indicates market values company more than its book value.
  • TaiwanJ Pharmaceuticals Co., Ltd. 52-week high Price to Book Ratio (P/B) is NA on January 14, 2025, which is NA below the current Price to Book Ratio (P/B).
  • TaiwanJ Pharmaceuticals Co., Ltd. 52-week low Price to Book Ratio (P/B) is NA on January 14, 2025, which is NA below the current Price to Book Ratio (P/B).
  • TaiwanJ Pharmaceuticals Co., Ltd. average Price to Book Ratio (P/B) for the last 52 weeks is NA.
Key data
Date Price to Book Ratio (P/B) Dividend Yield Free Cash Flow Yield Price to Earnings Ratio (P/E)
Market news
Taipei Exchange: 6549.TWO

TaiwanJ Pharmaceuticals Co., Ltd.

CEO Mr. Hung-Chang Yuan
IPO Date Oct. 21, 2015
Location
Headquarters No.2 ShengYi Road
Employees 12
Sector Health Care
Industries
Pharmaceuticals Biotechnology
Description

TaiwanJ Pharmaceuticals Co., Ltd., a specialty pharmaceutical company, develops and commercializes small molecules for chronic organ inflammation of metabolic, autoimmune, and infectious etiologies in Taiwan. The company also develops JKB-122 and JKB-121; and novel chemical entities for therapy to address chronic liver diseases and allergy/asthma. Its products target various diseases that include liver inflammation/liver fibrosis, non-alcoholic steatohepatitis, non-alcoholic fatty liver disease, autoimmune diseases, asthma, and atopic dermatitis. The company was incorporated in 2011 and is based in Zhubei, Taiwan.

StockViz Staff

January 15, 2025

Any question? Send us an email